Cross-lineage influenza B and heterologous influenza a antibody responses in vaccinated mice: Immunologic interactions and B/Yamagata dominance

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Skowronski, Danuta M ^a,b   Hamelin, Marie Eve ^c,d   Janjua, Naveed Z ^a,b   de Serres, Gaston ^c,e   Gardy, Jennifer L ^a,b   Rhéaume, Chantal ^d   Bouhy, Xavier ^d   Boivin, Guy ^c,d  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VICTORIA ANTIGEN; VIRUS ANTIGEN; YAMAGATA ANTIGEN;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; GENE SEQUENCE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MOUSE; NONHUMAN; SEASONAL INFLUENZA; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84862690493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038929     Document Type: Article

References (50)

1. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, et al. (1990) Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175: 59-68.
2. Shaw MW, Xu X, Li Y, Normand S, Ueki RT, et al. (2002) Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303: 1-8[rapid communication].
3. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8): 1-62 Available:http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf (Accessed 2012 May 22).
4. Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, et al. (2011) Randomized controlled trial of dose-response to influenza vaccine in children 6-23 months of age. Pediatrics 128: e276-89 Epub 2011 Jul 18. DOI:10.1542/peds.2010-2777.
5. Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, et al. (2011) Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J 30: 833-9.
6. Levandowski RA, Gross PA, Weksler M, Staton E, Williams MS, et al. (1991) Cross-reactive antibodies induced by a monovalent influenza B virus vaccine. J Clin Microbiol 29: 1530-2.
7. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, et al. (2006) Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 118: e570-e578.
8. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, et al. (2006) Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 118: e579-e585.
9. Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, et al. (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vacc Immunol 19: 209 DOI:10.1128/CVI.05441-11.
10. (2009) Product Monograph. Fluviral (2008-2 Available:http://www.gsk.ca/english/docs-pdf/Fluviral_2008-2009_PM_EN.pdf (Accessed 2012 May 22).
11. World Health Organization. WHO recommendations on the composition of influenza virus vaccines. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/en/index.html Accessed 2012 May 22.
12. (2011) Product Monograph. Fluviral (2010-2 Available:http://www.gsk.ca/english/docs-pdf/Fluviral_2010.pdf (Accessed 2012 May 22).
13. World Health Organization (2002) WHO manual on animal influenza diagnosis and surveillance. Available:http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf. Accessed 2012 May 22.
14. World Health Organization Global Influenza Surveillance Network (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. Available:http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf Accessed 2012 May 22.
15. Papenburg J, Baz M, Hamelin ME, Rheaume C, Carbonneau J, et al. (2011) Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol 18: 520-2.
16. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, et al. (2008) The Influenza Virus resource at the National Center for Biotechnology Information. J Virol 82: 596-601.
17. Katoh K, Asimenos G, Toh H, (2009) Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol 537: 39-64.
18. Product Monograph. Fluviral (2009-2010). Available:http://www.gsk.ca/english/docs-pdf/Fluviral_2009_PM.pdf Accessed 2012 May 22.
19. Belshe RB, (2010) The need for quadrivalent vaccine against seasonal influenza. Vaccine 28 (Suppl4): D45-53.
20. Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, et al. (2011) Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 30: 35-41.
21. Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, et al. (2012) Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR influenza research network (PCIRN) study. Vaccine 30: 3389-94.
22. Xie H, Jing X, Li X, Lin Z, Plant E, et al. (2011) Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 6: e16650.
23. Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, et al. (2011) Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study. Vaccine 29: 1228-34.
24. Morens DM, Burke DS, Halstead SB, (2010) The wages of original antigenic sin. Emerg Infect Dis 16: 1023-4.
25. Fazekas de St. Groth S, Webster RB, (1966) Disquisitions on original antigenic sin I: evidence in man. J Exp Med 124: 331-45.
26. Fazekas de St. Groth S, Webster RB, (1966) Disquisitions on original antigenic sin II: proof in lower creatures. J Exp Med 124: 347-61.
27. Kilbourne Ed, Cerini C, Khan MW, Mitchell JW, Ogra PL, (1987) Immunologic response of the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138: 3010-3013.
28. Siegrist C-A. Vaccine immunology. World Health Organization website. Available:http://www.who.int/immunization/documents/Elsevier_Vaccine_immunology.pdf Accessed 2012 May 26.
29. Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, et al. (2011) Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol Immunol 55: 783-89.
30. Ohfuji S, Fukushima W, Deguchi M, Kawabata K, Yoshida H, et al. (2011) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis. 203: 1301-8.
31. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P, (2010) AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 51: 668-77.
32. Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, et al. (2011) Predictors of immne response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine 29: 7913-9. Epub 2011 Aug 27.
33. Choi YS, Baek YH, Kang W, Nam SJ, Lee J, et al. (2011) Redued antibody responses to the pandemic (H1N10 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 18: 1519-23. Epub 2011 Aug 3.
34. Nolan T, McVernon J, Skello M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37-46.
35. Qiu C, Huang Y, Wang Q, Tian D, Zhang W, et al. (2012) Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. CID 54: 17-24.
36. Babiuk S, Skowronski DM, De Serres G, HayGlass K, Brunham RC, et al. (2004) Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol 72: 138-42.
37. Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, et al. (2004) Protollin™: a novel adjuvant for intranasal vaccines. Vaccine 22: 3691-97.
38. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin M-E, Koukavica I, et al. (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26: 3395-3403.
39. Zhou C, Zhou L, Chen Y-H, (2012) Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 30: 3463-69.
40. Van Maurik A, Sabarth N, Dacho HS, Bruhl P, Schwendinger M, et al. (2010) Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine 28: 1778-85.
41. Savard C, Guérin A, Droulin K, Bolduc M, Laliberté-Gagné M-E, et al. (2011) Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One 6: e21522.
42. D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, et al. (2008) Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnology Journal 6: 930-40.
43. Matsuoko Y, Lamirande EW, Subbarao K, (2009) The mouse model for influenza. Current Protocols in Microbiology 15G.3.1-15G.3.30. DOI:10.1002/9780471729259.mc15g03s13.
44. Huang BY, Wang XP, Tang WJ, Wang WL, Ruan L, (2011) The 50% effective dose (ED50a) of seasonal split influenza vaccine in mice. Chinese J Exp Clin Virol 25: 92-95 DOI:10.3760/cma.jissn.1003-9279.2011.02.004.
45. Armerding D, Rossiter H, Ghazzouli I, Liehl E, (1982) Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis 145: 320-330.
46. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
47. Katz JM, Hancock K, Xu X, (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti-Infect. Ther. 9: 669-83.
48. Monto AS, Maassab F, (1981) Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 13: 54-57.
49. Kendal AP, Cate TR, (1983) Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol 18: 930-34.
50. Van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, et al. (2008) Animal models in influenza vaccine testing. Expert Rev Vaccines 7: 783-93.